Name: Latest research reports of Sun Pharmaceutical Industries Ltd. authored by ICICI Direct and published by - Trendlyne research reports.
Item: Sun Pharmaceutical Industries Ltd.
Rating: 3
Author: ICICI Direct

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	15 Sep 2025	Sun Pharmaceutical	Consensus Share Price Target	1603.00	1930.16	-	20.41	buy	pdf Detailed Estimates
	23 May 2024	Sun Pharmaceutical	ICICI Direct Reco Target	1603.00	1530.00	1495.10 (7.22%)	Target met	Hold	pdf post cache	Broker Report Sun Pharma ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	22 May 2024	Sun Pharmaceutical	Motilal Oswal Target	1603.00	1810.00	1539.30 (4.14%)	Target met	Buy	pdf post cache	Broker Report The US and India businesses drive earnings growth Motilal Oswal Sun Pharma (SUNP) reported a slight miss at the operational level for 4QFY24. This was due to lower-than-expected sales in the ROW market and higher-than-expected opex for the quarter. pdf Copy Link Share on Share on Share on Share on Alert
	23 Apr 2024	Sun Pharmaceutical	Motilal Oswal Target	1603.00	1870.00	1484.65 (7.97%)	Target met	Buy	pdf post cache	Broker Report ‘Specialty’ way of driving growth prospects Motilal Oswal In this note, we explored the specialty pipeline of SUNP, examining products under development, the commercialized portfolio, and the competitive dynamics within each segment. pdf Copy Link Share on Share on Share on Share on Alert
	11 Mar 2024	Sun Pharmaceutical	Sharekhan Target	1603.00	1727.00	1584.30 (1.18%)	Target met	Buy	pdf post cache	Broker Report Sun Pharma Sharekhan pdf Copy Link Share on Share on Share on Share on Alert
	01 Feb 2024	Sun Pharmaceutical	SMC online	1603.00		1407.95 (13.85%)		Results Update	pdf post cache	Broker Report Sun Pharmaceuticals Industries SMC online pdf Copy Link Share on Share on Share on Share on Alert
	01 Feb 2024	Sun Pharmaceutical	BOB Capital Markets Ltd. Target	1603.00	1550.00	1407.95 (13.85%)	Target met	Hold	pdf post cache	Broker Report Sun Pharma (HOLD): Strong quarter driven by specialty business BOB Capital Markets Ltd. Strong quarter with revenue/EBITDA in line and reported PAT 4% ahead of Bloomberg consensus pdf Copy Link Share on Share on Share on Share on Alert
	02 Nov 2023	Sun Pharmaceutical	Motilal Oswal Target	1603.00	1310.00	1132.85 (41.50%)	Target met	Buy	pdf post cache	Broker Report Superior execution drives broad-based revenue growth Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	02 Nov 2023	Sun Pharmaceutical	BOB Capital Markets Ltd. Target	1603.00	1200.00	1132.85 (41.50%)	Target met	Hold	pdf post cache	Broker Report Sun Pharma (HOLD): Healthy quarter; better mix supports gross margin BOB Capital Markets Ltd. Q2 revenue/PAT grew 11%/5% YoY to Rs 122bn/Rs 24bn, largely in line with consensus pdf Copy Link Share on Share on Share on Share on Alert
	02 Nov 2023	Sun Pharmaceutical	ICICI Securities Limited Target	1603.00	1210.00	1132.85 (41.50%)	Target met	Accumulate	pdf post cache	Broker Report Branded drives growth; overheads dampen margins ICICI Securities Limited Sun Pharma (Sun)’s Q2FY24 performance was lower than our expectation (though in line with Street) due to higher overheads and lower sales of gRevlimid. Traction in branded generics business across India, emerging markets and RoW coupled with specialty business in US led to 11.3% growth in revenue. pdf Copy Link Share on Share on Share on Share on Alert
	12 Sep 2023	Sun Pharmaceutical	Geojit BNP Paribas Target	1603.00	1255.00	1145.25 (39.97%)	Target met	Buy	pdf post cache	Broker Report SUN PHARMA Geojit BNP Paribas pdf Copy Link Share on Share on Share on Share on Alert
more loading

Near 52W Low of ₹1553.05

Sun Pharmaceutical Industries Ltd. share price target

Sun Pharmaceutical Industries Ltd. has an average share price target of 2050.25. The consensus estimate represents an upside of 27.90% from the last price of 1603. View 14 reports from 8 analysts offering long-term price targets for Sun Pharmaceutical Industries Ltd..

Sun Pharma

The US and India businesses drive earnings growth

‘Specialty’ way of driving growth prospects

Sun Pharma

Sun Pharmaceuticals Industries

Sun Pharma (HOLD): Strong quarter driven by specialty business

Superior execution drives broad-based revenue growth

Sun Pharma (HOLD): Healthy quarter; better mix supports gross margin

Branded drives growth; overheads dampen margins

SUN PHARMA

Advisor Screeners